ClinicaliQ Trial Snapshot
- A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa — Active Not Recruiting • Phase III • NCT04901195.
- Bimekizumab safety study in patients with moderate to severe hidradenitis suppurativa over long-term treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS) Conditions: Hidradenitis Suppurativa Interventions: Bimekizumab Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 658 participants